FTX and urinary bladder carcinoma: This phenomenon is exemplified in various cancers: WEE2-AS1 and SNHG3 in colorectal cancer (47, 48); NEAT1 in endometrial cancer (49); LINC00355 in bladder cancer (50); SNHG3 in breast cancer (51); TUC338 in laryngeal squamous cell carcinoma (52); FTX in oral squamous cell carcinoma (53); and NNT-AS1 in pancreatic cancer (54).